Aldose Reductase Inhibitor, Epalrestat, Reduces Lipid Hydroperoxides in Type 2 Diabetes

Endocrine Journal

Ryuzo KAWAMORI¹  Chie OHMURA¹  Hirotaka WATADA¹  Kosuke AZUMA¹  Yoshio FUJITANI¹  Akio KANAZAWA¹  Fuki IKEDA¹  Tomoaki SHIMIZU¹  Tomoaki YOSHIHARA¹  Yasushi TANAKA¹  Takahisa HIROSE¹ 

[1] Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine

关键词: Oxidative stress;    Lipid hydroperoxides;    Diphenyl-1-pyrenylphosphine (DPPP);    Diabetes mellitus;    Aldose reductase inhibitor;    Epalrestat;   

DOI  :  10.1507/endocrj.K08E-237

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(38)Cited-By(9)The increased flux of polyol pathway induced by hyperglycemia is implicated in the pathogenesis of various complications associated with diabetic, which results in increased oxidative stress. Because oxidative stress causes tissue damage in patients with diabetes, searching for an effective strategy to reduce oxidative stress in clinical setting is important in order to prevent diabetic complications. The aim of this study was to evaluate the effects of aldose reductase inhibition on oxidative stress in patients with type 2 diabetes mellitus. The subjects of this study were 21 patients with type 2 diabetes. We compared the levels of various oxidative stress markers and antioxidants including plasma thiobarbituric acid-reactive substances, malondialdehyde-modified low-density lipoprotein, vitamin E, β-carotene and lipid hydroperoxides in erythrocytes at baseline with those measured after a 3-month course of epalrestat (150 mg/day), an aldose reductase inhibitor. While administration of epalrestat did not result in significant changes in plasma thiobarbituric acid-reactive substances, malondialdehyde-modified low-density lipoprotein, vitamin E, or β-carotene, it significantly reduced lipid hydroperoxides in erythrocytes. Given the importance of measuring lipid hydroperoxides in erythrocytes as an index of oxidative stress, these results highlight the potential usefulness of epalrestat in reducing oxidative stress in type 2 diabetes mellitus.

【 授权许可】

Unknown